(BIO) Bio-Rad Laboratories - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 7.700m USD | Total Return: 28.9% in 12m
Avg Turnover: 104M
EPS Trend: -94.1%
Qual. Beats: -1
Rev. Trend: -75.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Bio-Rad Laboratories, Inc. (BIO) is a global provider of life science research and clinical diagnostic products, operating through two primary business segments. The Life Science division focuses on tools for biological material separation and quantification, while the Clinical Diagnostics division develops test systems and quality controls for medical laboratories. Founded in 1952, the company maintains a diverse customer base ranging from academic institutions to pharmaceutical manufacturers.
The company utilizes a razor-and-blade business model, where the placement of specialized instruments drives recurring revenue through the continuous sale of proprietary reagents and consumables. Operating within the Life Sciences Tools & Services sub-industry, Bio-Rad is subject to the capital expenditure cycles of biotechnology firms and government research funding trends. For a deeper look into these financial drivers, you may find further insights on ValueRay.
Bio-Rad distributes its portfolio via a direct sales force and a network of international intermediaries. Its geographic footprint spans North America, Europe, and Asia, providing exposure to both established and emerging healthcare markets.
- Sartorius AG equity stake valuation causes significant quarterly net income volatility
- Bioprocessing demand recovery drives Life Science segment revenue and margin expansion
- Clinical Diagnostics recurring reagent sales provide stable long-term cash flow growth
- Academic and government research funding levels dictate Life Science instrument demand
- Global healthcare spending and diagnostic testing volumes impact Clinical Diagnostics segment profitability
| Net Income: 168.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.16 > 1.0 |
| NWC/Revenue: 78.19% < 20% (prev 99.56%; Δ -21.37% < -1%) |
| CFO/TA 0.05 > 3% & CFO 510.4m > Net Income 168.8m |
| Net Debt (-11.7m) to EBITDA (407.7m): -0.03 < 3 |
| Current Ratio: 3.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.0m) vs 12m ago -3.57% < -2% |
| Gross Margin: 51.87% > 18% (prev 0.54%; Δ 5.13k% > 0.5%) |
| Asset Turnover: 26.81% > 50% (prev 26.67%; Δ 0.14% > 0%) |
| Interest Coverage Ratio: 4.86 > 6 (EBITDA TTM 407.7m / Interest Expense TTM 49.3m) |
| A: 0.21 (Total Current Assets 2.94b - Total Current Liabilities 917.0m) / Total Assets 9.79b |
| B: 0.78 (Retained Earnings 7.65b / Total Assets 9.79b) |
| C: 0.02 (EBIT TTM 239.5m / Avg Total Assets 9.66b) |
| D: 2.52 (Book Value of Equity 7.41b / Total Liabilities 2.94b) |
| Altman-Z'' = 6.72 = AAA |
| DSRI: 1.02 (Receivables 439.5m/424.7m, Revenue 2.59b/2.54b) |
| GMI: 1.03 (GM 51.87% / 53.50%) |
| AQI: 1.03 (AQ_t 0.63 / AQ_t-1 0.61) |
| SGI: 1.02 (Revenue 2.59b / 2.54b) |
| TATA: -0.03 (NI 168.8m - CFO 510.4m) / TA 9.79b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 296.90 with a total of 399,491 shares traded.
Over the past week, the price has changed by +5.35%,
over one month by +3.35%,
over three months by +7.88% and
over the past year by +28.89%.
Bio-Rad Laboratories has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BIO.
- StrongBuy: 2
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 297 | 0% |
P/E Trailing = 47.8769
P/E Forward = 32.4675
P/S = 2.9732
P/B = 1.12
P/EG = 1.1905
Revenue TTM = 2.59b USD
EBIT TTM = 239.5m USD
EBITDA TTM = 407.7m USD
Long Term Debt = 802.9m USD (from longTermDebt, last quarter)
Short Term Debt = 436.7m USD (from shortTermDebt, last quarter)
Debt = 1.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 174.8m
Net Debt = -11.7m USD (calculated: Debt 1.55b - CCE 1.56b)
Enterprise Value = 7.69b USD (7.70b + Debt 1.55b - CCE 1.56b)
Interest Coverage Ratio = 4.86 (Ebit TTM 239.5m / Interest Expense TTM 49.3m)
EV/FCF = 21.52x (Enterprise Value 7.69b / FCF TTM 357.2m)
FCF Yield = 4.65% (FCF TTM 357.2m / Enterprise Value 7.69b)
FCF Margin = 13.79% (FCF TTM 357.2m / Revenue TTM 2.59b)
Net Margin = 6.52% (Net Income TTM 168.8m / Revenue TTM 2.59b)
Gross Margin = 51.87% ((Revenue TTM 2.59b - Cost of Revenue TTM 1.25b) / Revenue TTM)
Gross Margin QoQ = 52.25% (prev 49.80%)
Tobins Q-Ratio = 0.79 (Enterprise Value 7.69b / Total Assets 9.79b)
Interest Expense / Debt = 3.17% (Interest Expense 49.3m / Debt 1.55b)
Taxrate = 23.67% (235.6m / 995.5m)
NOPAT = 182.8m (EBIT 239.5m * (1 - 23.67%))
Current Ratio = 3.21 (Total Current Assets 2.94b / Total Current Liabilities 917.0m)
Debt / Equity = 0.23 (Debt 1.55b / totalStockholderEquity, last quarter 6.85b)
Debt / EBITDA = -0.03 (Net Debt -11.7m / EBITDA 407.7m)
Debt / FCF = -0.03 (Net Debt -11.7m / FCF TTM 357.2m)
Total Stockholder Equity = 7.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.75% (Net Income 168.8m / Total Assets 9.79b)
RoE = 2.40% (Net Income TTM 168.8m / Total Stockholder Equity 7.04b)
RoCE = 3.05% (EBIT 239.5m / Capital Employed (Equity 7.04b + L.T.Debt 802.9m))
RoIC = 1.96% (NOPAT 182.8m / Invested Capital 9.31b)
WACC = 7.27% (E(7.70b)/V(9.25b) * Re(8.25%) + D(1.55b)/V(9.25b) * Rd(3.17%) * (1-Tc(0.24)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.67 | Cagr: -2.92%
[DCF] Terminal Value 76.38% ; FCFF base≈347.2m ; Y1≈370.4m ; Y5≈443.1m
[DCF] Fair Price = 314.2 (EV 6.81b - Net Debt -11.7m = Equity 6.82b / Shares 21.7m; r=8.35% [WACC [floored]]; 5y FCF grow 7.56% → 2.50% )
EPS Correlation: -94.08 | EPS CAGR: -8.18% | SUE: -1.40 | # QB: -1
Revenue Correlation: -75.26 | Revenue CAGR: -2.26% | SUE: 0.20 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.75 | Chg30d=-28.74% | Revisions=-43% | Analysts=3
EPS next Quarter (2026-09-30): EPS=2.31 | Chg30d=-14.93% | Revisions=-43% | Analysts=3
EPS current Year (2026-12-31): EPS=9.00 | Chg30d=-12.26% | Revisions=-50% | GrowthEPS=-9.2% | GrowthRev=-0.6%
EPS next Year (2027-12-31): EPS=9.72 | Chg30d=-14.33% | Revisions=-50% | GrowthEPS=+8.0% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: -50%